oblimersen (G3139)

targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions

Also Known As:

G3139; DNA, D(P-thio)(T-C-T-C-C-C-A-G-C-G-T-G-C-G-C-C-A-T); DNA, D(P-thio)(T-C-T-C-C-C-A-G-C-G-T-G-C-G-C-C-A-T) hepatadecasodium salt; G 3139; G-3139 oligonucleotide; G3139 oligonucleotide; Genasense; bcl-2 antisense oligodeoxynucleotide; oblimersen sodium

Networked: 154 relevant articles (16 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stein, C A: 16 articles (04/2009 - 12/2001)
2.	Benimetskaya, Luba: 12 articles (04/2009 - 10/2003)
3.	Marcucci, Guido: 10 articles (01/2010 - 01/2003)
4.	Liu, Shujun: 9 articles (01/2010 - 04/2005)
5.	Miller, Paul: 9 articles (04/2009 - 05/2004)
6.	Lee, Robert J: 8 articles (06/2011 - 05/2006)
7.	Lai, Johnathan C: 7 articles (04/2007 - 05/2004)
8.	Lee, L James: 6 articles (06/2011 - 06/2009)
9.	Yu, Bo: 6 articles (06/2011 - 06/2009)
10.	Chanan-Khan, Asher: 5 articles (06/2011 - 11/2004)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 01/01/2007 - "Genta believes that analysis sought to discredit the finding that treatment with oblimersen significantly increased progression-free survival; ODAC previously agreed this endpoint would support full approval in the absence of a survival improvement in patients with advanced melanoma.A rolling NDA submission was submitted to the FDA in the third quarter of 2003; however, Genta and Aventis withdrew the NDA after the application failed to gain marketing approval from the FDA's Oncology Drug Advisory Committee (ODAC). " 06/01/2014 - "To confirm and expand on this observation, we conducted a prospective double-blind, placebo-controlled study to determine whether oblimersen augmented the efficacy of Dac in advanced melanoma patients with low-normal baseline LDH levels. " 07/01/2009 - "LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)." 01/01/2007 - "Genta will conduct another phase III study of oblimersen in patients with advanced melanoma. " 01/01/2007 - "In May 2004, ODAC voted that phase III trial results did not provide substantial evidence of effectiveness to outweigh toxicity of oblimersen treatment in patients with metastatic melanoma. "
2.	Neoplasms (Cancer) 07/15/2006 - "When treatment was delayed until tumor was established, G3139 in combination with CDDP significantly inhibited tumor growth compared to CDDP or CDDP + control oligo, and cured 69% animals with established tumors. " 06/01/2009 - "In addition, Tf-LP-G3139 was found to be more effective in tumor growth inhibition and prolonging mouse survival than free G3139. " 01/01/2007 - "Why G3139 works poorly in cancer trials but might work well against HIV." 06/01/2006 - "Currently, clinical trials on G3139 for diverse tumors are underway in phase II and phase III. However, basic investigations of bcl-2 antisense ODN (G3139) and reverse ODN (G3622) have not been fully examined. " 11/01/2004 - "A phase I trial in patients with refractory/relapsed CLL showed that patients with CLL were more sensitive to oblimersen than patients with solid tumors. "
3.	Prostatic Neoplasms (Prostate Cancer) 10/01/2010 - "Radiation was shown to increase intracellular and intratumoural penetration of oblimersen, confirming previous results obtained in prostate cancer xenograft models. " 02/01/2005 - "Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer." 10/01/2003 - "Although treatment of PC3 prostate cancer cells with G3139, which contains two CpG motifs, causes a dramatic decrease in bcl-2 protein expression after 3 days, it did not result in significant cellular apoptosis, as it does in many other cell lines. " 12/01/2011 - "This study aimed to investigate the efficacy of G3139 combined with epirubicin in the androgen-independent prostate cancer. " 05/15/2005 - "A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer."
4.	Lymphoma (Lymphomas) 12/01/2004 - "G3139, under optimal transfection conditions, decreased the proliferation rate of lymphoma cells by 60-75% when compared with controls. " 12/01/2004 - "Our findings suggest that Bcl-2 downregulation by G3139, followed by the administration of rituximab is an efficient anti-tumour strategy associated with improved survival in lymphoma-bearing SCID mice." 08/01/2007 - "[Combinational effects of bcl-2 antisense oligodeoxynucleotide and Rituximab on proliferation and apoptosis of B-lymphoma Raji cells]." 12/01/2004 - "Treatment of lymphoma-bearing SCID mice with G3139 for two consecutive days prior to each rituximab dose resulted in better disease control and survival than treatment with either agent alone or controls. " 04/01/1997 - "An 18-mer full-phosphorothioate oligonucleotide with sequence antisense to the first six codons of the open reading frame of bcl-2 (G3139) has shown efficacy against the DoHH2 lymphoma implanted in severe combined immunodeficient mice. "
5.	Multiple Myeloma 01/01/2007 - "Oblimersen received orphan drug status in the US and EU for multiple myeloma in September 2001. " 01/01/2003 - "These data support further clinical evaluation of G3139 therapy in multiple myeloma." 09/01/2006 - "Randomized phase III trials are currently underway to evaluate whether the combined use of Oblimersen with standard treatment is superior to standard treatment alone in chronic lymphocytic leukaemia, malignant melanoma and multiple myeloma. " 01/01/2007 - "Genta has reported results from randomised phase III trials of oblimersen in four different indications: malignant melanoma, chronic lymphocytic leukaemia (CLL), multiple myeloma and acute myleoid leukaemia (AML). " 01/01/2007 - "In addition, fast-track designation was given to oblimersen by the FDA in the same month.A phase I/II clinical study (NCT00062244) of oblimersen was conducted by the NCI in patients with Waldenstrom's macroglobulinaemia, a disease that is similar to multiple myeloma. "

Related Drugs and Biologics

1.	oblimersen (G3139)
2.	Antisense Oligonucleotides
3.	Dacarbazine (DIC)
4.	Docetaxel (Taxotere)
5.	Doxorubicin (Adriamycin)
6.	Oligonucleotides
7.	Hormones (Hormone)
8.	Cyclophosphamide (Cytoxan)
9.	Proteins (Proteins, Gene)
10.	Oligodeoxyribonucleotides

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Therapeutics
4.	Intravenous Infusions
5.	Castration